Metabolomics Signatures of serotonin reuptake inhibitor (Escitalopram), serotonin norepinephrine reuptake inhibitor (Duloxetine) and Cognitive Behavior Therapy on Key Neurotransmitter Pathways in Major Depressive Disorder
Preprint
Abstract
Metabolomics provides powerful tools that can inform about heterogeneity in disease and response to treatments. In this study, we employed an electrochemistry-based targeted metabolomics platform to assess the metabolic effects of three randomly-assigned treatments: escitalopram, duloxetine, and Cognitive Behavior Therapy (CBT) in 163 treatment-naïve outpatients with major depressive disorder. Serum samples from baseline and 12 weeks post-treatment were analyzed using targeted liquid chromatography-electrochemistry for metabolites related to tryptophan, tyrosine metabolism and related pathways. Changes in metabolite concentrations related to each treatment arm were identified and compared to define metabolic signatures of exposure. In addition, association between metabolites and depressive symptom severity (assessed with the 17-item Hamilton Rating Scale for Depression [HRSD 17 ]) and anxiety symptom severity (assessed with the 14-item Hamilton Rating Scale for Anxiety [HRSA 14 ]) were evaluated, both at baseline and after 12 weeks of treatment. Significant reductions in serum serotonin level and increases in tryptophan-derived indoles that are gut bacterially derived were observed with escitalopram and duloxetine arms but not in CBT arm. These include indole-3-propionic acid (I3PA), indole-3-lactic acid (I3LA) and Indoxyl sulfate (IS), a uremic toxin. Purine-related metabolites were decreased across all arms. Different metabolites correlated with improved symptoms in the different treatment arms revealing potentially different mechanisms between response to antidepressant medications and to CBT.Keywords
This publication has 35 references indexed in Scilit:
- Heterogeneity in major depressive disorder: The need for biomarker-based personalized treatments2022
- Side effects of antidepressants2022
- Regional metabolic heterogeneity in anterior cingulate cortex in major depressive disorder: A multi-voxel 1H magnetic resonance spectroscopy studyJournal of Affective Disorders, 2022
- Metabolomic signatures of intravenous racemic ketamine associated remission in treatment-resistant depression: A pilot hypothesis generating studyPsychiatry Research, 2022
- The relationship between plasma serotonin and kynurenine pathway metabolite levels and the treatment response to escitalopram and desvenlafaxineBrain, Behavior, and Immunity, 2020
- Plasma serotonin levels are associated with antidepressant response to SSRIsJournal of Affective Disorders, 2019
- Purine metabolism is dysregulated in patients with major depressive disorderPsychoneuroendocrinology, 2016
- TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomicsMolecular Psychiatry, 2016
- A Cognitive–Emotional Biomarker for Predicting Remission with Antidepressant Medications: A Report from the iSPOT-D TrialNeuropsychopharmacology, 2014
- Association of the C(–1019)G 5-HT1A functional promoter polymorphism with antidepressant responseInternational Journal of Neuropsychopharmacology, 1999